PURIBLOOD MEDICAL CO., LTD.
Update：2026/08/06
Industries
Main Industry
Health Care
Main Product/Service
PuriBlood Leukocyte Reduction Filter
Leukoreduction before transfusion is proved to benefit in reducing the adverse reaction and pathogen transmission in blood transfusion since 1985.
With our patented technology, the filter can precisely capture WBCs an
Leukoreduction before transfusion is proved to benefit in reducing the adverse reaction and pathogen transmission in blood transfusion since 1985.
With our patented technology, the filter can precisely capture WBCs an
Founded Year
2016
Unified Business No.
42770331
Status
Active
Number of Employees
0
Total Paid-in
Capital
142,300,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2021)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PuriBlood developed a unique technology for blood cell separation that is supported by a world-class research center the R and D center for membrane technology. PuriBlood is committed to improving the blood filtration process with the innovative technology of zwitterionic-bias surface coating technology. Filter housing transparent housingfacilitates monitoring priming and blood flow.
